Spotlight On: 2026 Healthcare Investment and Financing Transaction Conference

Leveraging advantages in efficiency, talent, and quality, China's innovative drug sector has grown into an indispensable force within the global pharmaceutical innovation system. In cutting-edge technology areas such as bispecific antibodies, antibody-drug conjugates (ADCs), and small nucleic acid therapeutics, China has established globally competitive R&D clusters that continue to drive robust cross-border deal activity. In 2025, the global share of innovation-driven pharmaceutical transactions involving China exceeded 50% for the first time, with total transaction value reaching a historic high of US$135.7 billion. Despite this milestone, only about 5% of China's new drug pipelines have entered the transaction spotlight, leaving a wealth of high-value Chinese innovative drug assets yet to be discovered by global partners.

How to identify and secure early positions in globally promising technology tracks? How to efficiently allocate capital to project assets with true differentiation and high technical barriers? How to ensure that quality Chinese innovation gains visibility among partners and achieves maximum value? These are the core questions confronting all industry stakeholders.

The 2026 Healthcare Investment and Financing Transaction Conference is designed with the guiding principle ofGather Strength for Innovation, Make Deals Happen. Leveraging PharmCube's comprehensive industry chain data and intelligent analytics capabilities—and grounded in real-time tracking of global drug pipelines, technology tracks, BD transactions, and investment trends—the conference will feature industry dialogues, award presentations, and high-potential project roadshows. We cordially invite you to attend this data-driven, win-win industry gathering. Here, deals take shape and value multiplies.

01

Basic Information

Time:May 20-21, 2026
Address: Shanghai
Organizers: ZFIC Alliance, Pharmcube
Attendees: Domestic and international Pharmaceutical and biotech company management, BD, R&D, strategic leaders, investors, etc.

Scan the QR code to register

https://www.bagevent.com/event/9153788

*Free registration, you can attend after approval by the organizer

02

Conference Highlights

High-potential project roadshow

Based on the track ranking function of the Nextpharma database, we screen leading projects in global R&D progress within specific tracks, and invite for roadshows based on quantitative analysis indicators

Brand Rankings

Leveraging the comprehensive industrial chain data and quantitative evaluation models of Pharmacube, we have selected pioneering technology benchmark enterprises that serve as annual trendsetters, releasing the Top 15 list

Empowered by BD Practical Experience

Invite enterprises that have successfully completed BD transactions to share their experiences, and provide participants with an action guide for BD transactions based on their own successful practical experiences

Overseas Resource Links

Invite leading investment institutions and pharmaceutical companies from home and abroad to China, helping domestic and international enterprises connect resources more conveniently and efficiently, and facilitating project transactions and the expansion of international business cooperation.

03

Agenda Draft

04

Snapshots of Previous Conference

Swipe left or right to view

05

Organizer Introduction

Scan the QR code to register

https://www.bagevent.com/event/9153788

About ZFICAlliance

The FIC Innovative Drug Strategic Development Alliance (ZFIC), initiated jointly by the Beijing Medical and Technology Development Center, Pharmcube, and Hotgene, is committed to the mission of "making China's innovative drugs benefit people around the world." It aims to build a global FIC innovative drug empowerment platform. By gathering core industry forces, it seeks to connect the entire scenario chain of China's innovative drugs, including "translation - R&D - registration - access," to help FIC innovative drug companies break through development bottlenecks, promote the improvement of the innovative drug industry ecosystem, and drive the sustainable R&D, international cooperation, and value realization of source innovation drugs in Beijing and even China. The alliance now has more than 40 member units.

About Pharmcube

Pharmcube was founded in 2015 and has established a professional pharmaceutical data standard system. It deeply integrates cutting-edge data engineering and artificial intelligence technologies to agilely monitor pharmaceutical research and development and competitive intelligence in major countries around the world, keeping real-time track of global pharmaceutical innovation, market trends, and dynamics. It provides high-quality data products and service support for industry decision-making.

Based on high-quality industry data and research capabilities, Pharmcube has gradually become a think tank force that supports and leads the pharmaceutical innovation ecosystem in China. It has undertaken data support services for the national 'Major New Drug Creation' projects for many years, and routinely serves multiple ministries including the National Development and Reform Commission, the Ministry of Industry and Information Technology, the National Medical Products Administration, the National Healthcare Security Administration, and the National Health Commission through data research reports. It has published several papers in top international journals such as Nature, with a cumulative impact factor exceeding 1100.